AI Article Synopsis
- Vasomotor symptoms (VMS), such as hot flashes and night sweats, commonly disrupt the quality of life during menopause, and fezolinetant is a non-hormonal treatment approved by the FDA to address these symptoms.
- The study involved analyzing six randomized controlled trials with a total of 3,301 postmenopausal women, demonstrating that fezolinetant significantly reduced both the frequency and severity of VMS episodes compared to a placebo at four and twelve weeks.
- Although fezolinetant showed positive results in alleviating VMS, it also presented increased risks for certain adverse effects, including fatigue and elevated liver enzyme levels, indicating a need for careful consideration of its safety
Article Abstract
Background & Objective: Vasomotor symptoms (VMS) are the most common symptoms during menopause including hot flushes and night sweats. They are highly disruptive to the quality of life. Fezolinetant is an FDA-approved non-hormonal selective neurokinin3 receptor antagonist for the treatment of VMS. In this study, we aim to assess the efficacy and safety of fezolinetant for VMS associated with menopause.
Methods: Databases were searched until September 2023 for relevant studies comparing fezolinetant against placebo. Data was extracted into an online form and analyzed using RevMan (Version 5.4.1). The GRADE approach was conducted to evaluate the quality of evidence regarding efficacy outcomes. We included randomized controlled trials (RCTs) comparing fezolinetant to placebo in postmenopausal women experiencing VMS. Exclusion criteria comprised studies involving participants with contraindications to fezolinetant or those evaluating its efficacy for indications other than VMS associated with menopause.
Results: Six studies were included in this study involving 3301 patients. Compared to placebo, fezolinetant reduced the frequency of VMS episodes from baseline (SMD = -0.64, 95 % CI [-0.77, -0.5]) and (SMD = -0.63, 95 % CI [-0.72, -0.53] at weeks 4 and 12 respectively. Additionally, fezolinetant reduced VMS severity score (SMD = -0.59, 95 %CI [-0.77, -0.42]) and (SMD = -0.4, 95 % CI [-0.54, -0.27]) at weeks 4 at 12 respectively. These reductions were positively reflected on Menopause specific quality of life score (SMD = -0.46, 95 %CI [-57, -0.34]), (SMD = -0.37, 95 %CI [-0.48, -0.25]) at weeks 4 and 12 respectively. Regarding safety analysis, fezolinetant showed increased risk for drug-related TEAEs (RR = 1.47, 95 %CI [1.06,2.04]), serious TEAEs (RR = 1.67, 95 %CI [1.09,2.55]), fatigue (RR = 4.05, 95 %CI [1.27,12.88]), arthralgia (RR = 2.83, 95 %CI [1.02,7.8]) and ALT or AST > 3 times (RR = 2, 95 %CI [1.12,3.57]), with no other statistically significant difference regarding other safety terms.
Conclusion: Fezolinetant has demonstrated efficacy in reducing the frequency and severity of VMS in postmenopausal women, leading to an improvement in their quality of life. These findings suggest that Fezolinetant may serve as a viable alternative to hormonal therapy for managing VMS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejogrb.2024.04.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The synergetic effect of edaravone and scutellarin in the MPP(+)-induced cell model of Parkinson's disease.
Histol Histopathol
January 2025
Department of Neurology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang Jiangsu, PR China.
Parkinson's disease (PD) is a limb movement disorder caused by the degeneration of brain neurons and seriously affects the quality of life of the elderly. However, the current drugs are symptomatic treatments that cannot prevent or delay the development of the disease. Targeted therapy for pathogenesis may be the direction of development in the future.
View Article and Find Full Text PDFChildren's palliative care perceptions and educational needs among healthcare professionals in humanitarian settings.
Palliat Support Care
January 2025
Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Objectives: Explore humanitarian healthcare professionals' (HCPs) perceptions about implementing children's palliative care and to identify their educational needs and challenges, including learning topics, training methods, and barriers to education.
Methods: Humanitarian HCPs were interviewed about perspectives on children's palliative care and preferences and needs for training. Interviews were transcribed, coded, and arranged into overarching themes.
What are family caregivers' experiences of coordinating end-of-life care at home? A narrative review.
Palliat Support Care
January 2025
School of Nursing and Midwifery, University of Plymouth, Plymouth, UK.
Objectives: People with life-limiting diseases, who are no longer receiving active or curable treatment, often state their preferred place of care and death as the home. This requires coordinating a multidisciplinary approach, using available health and social care services to synchronize care. Family caregivers are key to enabling home-based end-of-life support; however, the 2 elements that facilitate success - coordination and family caregiver - are not necessarily associated as being intertwined or one and the same.
View Article and Find Full Text PDFThe contribution of clock genes BMAL1 and PER2 in osteoarthritis-associated pain.
Neurobiol Pain
December 2024
Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL, USA.
Joint pain is the primary symptom of osteoarthritis (OA) and the main motivator for patients to seek medical care. OA-related pain significantly restricts joint function and diminishes quality of life. Despite the availability of various pain-relieving medications for OA, current treatment strategies often fall short in delivering adequate pain relief.
View Article and Find Full Text PDFStress, perceived competence and guilt as predictors of depression in parents with chronic pain.
Front Psychol
January 2025
Department of Psychology, Rey Juan Carlos University, Alcorcón, Spain.
Introduction: Suffering from chronic pain (CP) and coping with parenthood can be challenging for parental mental health. Pain can hinder the ability to deal with demands related to parenthood, which can negatively affect their psychological well-being because of unmet caregiving expectations.
Methods: Considering the limited amount of research regarding the mental health of parents with CP, the study's main aim was to test a predictive model based on previous scientific literature, using structural equation analysis, in which parental competence and parental guilt partially mediate the relationship between parental stress and depression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!